RORgammaT inhibitors

1. A compound according to Formula I

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is C(O), SO or SO 2 ,

Y is CH or N;

n=0, 1, 2, 3 or 4;

A 4 -A 7 are independently N or CR 4 , CR 5 , CR 6 or CR 7 , respectively, with the proviso that no more than two of the four positions A 4 -A 7 can be simultaneously N, wherein A 4 is N, A 5 is CR 5 , A 6 is CR 6 , and A 7 is CR 7 ;

R 1 is (i) (C 3-7 )cycloalkyl or (C 3-5 )heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(O)—, (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens; (ii) (C 2-9 )heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(O)—, (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens; or (iii) (C 6-14 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(O)—, (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy are optionally substituted with one or more halogens;

R 2 is C(O)OH, 5-tetrazoylyl, HOC(CF 3 ) 2 , C(O)OH(C 1-10 )alkyl, (C 1-10 )alkylsulfoxyaminocarbonyl; or carbamoyl;

R 3 is hydrogen, halogen, cyano, nitro, hydroxy, (C1-3)alkylC(O)O—, (C 1-4 )alkyl, or (C 1-4 )alkoxy, wherein (C 1-4 )alkyl and (C 1-4 )alkoxy are optionally substituted with one or more halogen;

R 4 -R 7 independently are H, halogen, amino, cyano, hydroxy, (C 1-3 )alkoxy, (C 1-4 )alkyl, (C 0-10 )alkyl)aminocarbonyl, (di)(C 1-6 )alkylaminocarbonyl or amino(C 1-4 )alkyl, wherein (C 1-3 )alkoxy, (C 1-4 )alkyl, (C 0-10 )alkyl)aminocarbonyl, (di)(C 1-6 )alkylaminocarbonyl and amino(C 1-4 )alkyl are optionally substituted with one or more halogen, hydroxyl or (C 1-3 )alkoxy; or a group having the formula

 optionally substituted with one or more of the following: (C 1-10 )alkyl, halogen, amino, cyano, hydroxy, (C 1-3 )alkoxy, and wherein m is 1, 2, 3, or 4.

2. A compound according to Formula Ia

or a pharmaceutically acceptable salt or solvate thereof, wherein

X represents C(O), SO or SO 2 ,

Y is CH or N;

A 4 -A 7 are independently N or CR 4 , CR 5 , CR 6 or CR 7 , respectively, with the proviso that no more than two of the four positions A 4 -A 7 can be simultaneously N, wherein A 4 is N, A 5 is CR 5 , A 6 is CR 6 , and A 7 is CR 7 ;

R 1 is (C 3-7 )cycloalkyl or (C 3-5 )heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, hydroxy, H 2 NC(O)—, or (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 alkyl or (C 1-3 )alkoxy, all optionally substituted with one or more halogens or;

R 1 is (C 2-9 )heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(O)—, or (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, all optionally substituted with one or more halogens or;

R 1 is (C 6-14 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(O)—, or (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, all optionally substituted with one or more halogens;

R 2 is C(O)OH, 5-tetrazoylyl, or HOC(CF 3 ) 2 ;

R 3 is independently selected from hydrogen, halogen, cyano, nitro or (C 1-4 )alkyl, optionally substituted with one or more halogens; and

R 4 -R 7 independently are H, halogen, amino, cyano, hydroxy, (C 1-3 )alkoxy, (C 1-4 alkyl, optionally substituted with one or more halogens.

3. The compound of claim 1 , wherein Y is N.

4. The compound of claim 3 , wherein

X is C(O) or SO 2 ;

R 1 is (i) (C 3-7 )cycloalkyl or (C 3-5 )heterocycloalkyl, both optionally substituted with one or more groups selected from (C 1-4 )alkyl or halogen; (ii) (C 2-9 )heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (C 1-4 )alkyl; or (iii) (C 6-14 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl, (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.

5. The compound of claim 4 , wherein

R 1 is (C 2-9 )heteroaryl or (C 6-14 )aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alky or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.

6. The compound of claim 5 wherein R 1 is phenyl, naphthyl, pyridinyl, quinolinyl, benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.

7. The compound of claim 6 , wherein R 1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.

8. The compound of claim 7 , wherein R 2 is C(O)OH.

9. The compound of claim 1 having Formula Ib

or a pharmaceutically acceptable salt or solvate thereof.

10. The compound of claim 9 having Formula Ic

or a pharmaceutically acceptable salt or solvate thereof, wherein,

X is C(O) or SO 2

R 8 is selected from halogen, amino, cyano, nitro, hydroxy, H 2 NC(O)—, (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (di)(C 1-6 )alkylaminocarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy are optionally substituted with one or more halogens; and

x is 0, 1, 2, 3, 4 or 5.

11. The compound of claim 10 having Formula Id

or a pharmaceutically acceptable salt or solvate thereof.

12. The compound of claim 11 having Formula Ie

or a pharmaceutically acceptable salt or solvate thereof.

13. A compound according to claim 1 selected from:

4-(1-(2,6-dichlorbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

4-(1-(2-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

4-(1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid;

4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;

methyl4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate;

sodium4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate;

3-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

2-(4-(1(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)phenyl)acetic acid;

(2-chloro-6-(trifluoromethyl)phenyl)(3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methanone;

4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-methylbenzoic acid;

3-chloro-4(1-(2-chloro6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin3-yl)-2-fluorobenzoic acid;

4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2methoxybenzoic acid;

2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-5-fluorobenzoic acid;

4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2,5-difluorobenzoic acid;

5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid;

4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid;

2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;

4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyeazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid;

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients.

15. The pharmaceutical composition of claim 14 , which further comprises at least one additional therapeutically active agent.

16. 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid, having the formula

17. A pharmaceutically acceptable salt of the compound of claim 16 .

18. A pharmaceutical composition comprising the compound of claim 16 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

19. The pharmaceutical composition of claim 18 , which further comprises at least one additional therapeutically active agent.